A woman's story of literal strength shows how ovarian cancer can be missed—and the lighthearted recovery milestone every care ...

A common blood test for ovarian cancer is more likely to fall short for Black and Native American women, according to a new ...

A federal judge rejected Johnson & Johnson’s third attempt to use bankruptcy to set up a multibillion-dollar trust fund to ...

Registration for the 35th annual Especially for You Race Against Breast Cancer opens April 1.Set for Sunday, Oct. 5, the race ...

The phase 3 trial showed relacorilant with chemotherapy improved progression-free and overall survival in platinum-resistant ...

Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to ...

Corcept Therapeutics shares nearly doubled in premarket trading Monday after the company said it received positive data from its phase 3 ovarian cancer treatment trial. Shares rose 93% ahead of the ...

Opens in a new tab or window Analysis of data from over 1.2 million US patients with gynecologic cancers between 2004 and 2020 revealed a significant shift towards surgical de-escalation ...

The Company expects to submit a New Drug Application to the Food and Drug Administration in the third quarter of 2025.

Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the analytical validation of NavDx+Gyn, an important extension of the NavDx® blood test.

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.